Sort   by:  
 Page size 
UnknownIndacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Not available
S-EPMC6011394 | biostudies-literature
UnknownThe effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials.
Not available
S-EPMC5440002 | biostudies-literature
UnknownEarly efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
Not available
S-EPMC5182036 | biostudies-literature
UnknownImmunologic resilience and COVID-19 survival advantage.
Not available
S-EPMC8425719 | biostudies-literature
UnknownThe 15-Year Survival Advantage: Immune Resilience as a Salutogenic Force in Healthy Aging.
Not available
S-EPMC12266754 | biostudies-literature
UnknownComorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans.
Not available
S-EPMC4329763 | biostudies-literature
UnknownAssociation between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease.
Not available
S-EPMC5003216 | biostudies-literature
UnknownImmune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection.
Not available
S-EPMC10264401 | biostudies-literature
UnknownChronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes.
Not available
S-EPMC3184233 | biostudies-literature
UnknownCOPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.
Not available
S-EPMC7020846 | biostudies-literature
Sort   by:  
 Page size